Skip to Main content Skip to Navigation
New interface
Journal articles

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

Axel Le Cesne 1 Isabelle Ray-Coquard 2 Binh Nguyen Bui Antoine Adenis 3 Maria Rios 4 François Bertucci 5 Florence Duffaud 6 Christine Chevreau 7 Didier Cupissol 8 Angela Cioffi Jean-François Emile 9 Sylvie Chabaud 10 David Pérol 11 Jean-Yves Blay 2 
1 Département de médecine oncologique [Gustave Roussy]
2 Department of Medical Oncology [Lyon]
3 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
4 CAV - Centre Alexis Vautrin
5 CRCM - Centre de Recherche en Cancérologie de Marseille
6 Neuro-Oncologie [Hôpital de la Timone - APHM]
7 Institut Claudius Regaud
8 IRCM - U896 Inserm - UM1 - Institut de recherche en cancérologie de Montpellier
9 Service d'anatomie pathologique [CHU Ambroise-Paré]
10 UBET - Unité de Biostatistique et d'Evaluation des Thérapeutiques
11 Department of Biostatistics
Document type :
Journal articles
Complete list of metadata
https://hal-amu.archives-ouvertes.fr/hal-03623804
Contributor : François Bertucci Connect in order to contact the contributor
Submitted on : Tuesday, March 29, 2022 - 7:33:35 PM
Last modification on : Monday, November 28, 2022 - 10:38:07 AM

Identifiers

Collections

CNRS | UNIV-AMU | ICR | FNCLCC | VALDAURELLE | IGR | LAMBRET | PAOLI_CALMETTES | VAUTRIN | BS | UNIV-MONTPELLIER | UNIV-LILLE | IRCM | CRCM

Citation

Axel Le Cesne, Isabelle Ray-Coquard, Binh Nguyen Bui, Antoine Adenis, Maria Rios, et al.. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncology, 2010, 11 (10), pp.942-949. ⟨10.1016/s1470-2045(10)70222-9⟩. ⟨hal-03623804⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

13